UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen (2)

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this document and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and healthcare cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

1. USL261 has not been submitted to or approved by the FDA. These statements solely reflect the opinions of the authors.

2. Id.

3. This statement has not been submitted to the FDA and solely reflects the opinions of the authors.

4. Haut SR. Current Opinion in Neurology 2015, 28:143-150

5. USL261 has not been submitted to or approved by the FDA. These statements solely reflect the opinions of the authors.

CONTACT: UCB Corporate Communications, France Nivelle, GlobalCommunications, UCB, T +32-2-559-9178, france.nivelle@ucb.com or LaurentSchots, Media Relations, UCB T +32-2-559-92-64, laurent.schots@ucb.com,Proximagen / ACOVA media contact: Chad Martinson, CEO, ACOVA, Inc.,Director, Proximagen, LLC, T +1(952)977-8717, cmartinson@AcovaHealth.com,UCB Investor Relations, Antje Witte, Investor Relations, UCB, T+32.2.559.94.14, antje.witte@ucb.com or Isabelle Ghellynck, InvestorRelations, UCB, T +32.2.559.9588, isabelle.ghellynck@ucb.com